What percentage of patients with juvenile ceroid lipofuscinosis (JCL) exhibit MRI changes, such as cerebral or cerebellar atrophy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

MRI Changes in Juvenile Ceroid Lipofuscinosis

MRI abnormalities are present in 100% of patients with juvenile neuronal ceroid lipofuscinosis (JNCL) who undergo brain imaging, though the severity and specific patterns vary with disease stage and patient age. 1, 2

Universal MRI Findings

All patients with JNCL demonstrate diffuse cerebral atrophy on MRI, making this the most consistent neuroimaging feature of the disease. 2 However, the timing and severity of atrophy progression correlates with age:

  • Mild to moderate cerebral atrophy develops in approximately 47% (14 of 30) of patients, predominantly affecting those over 14 years of age 1
  • Cerebellar atrophy occurs in 40-55% of JNCL patients, with higher rates (55%) specifically in the juvenile subtype compared to other NCL variants 2
  • Progressive hippocampal atrophy occurs at an annual rate of 3.3% volume loss, exceeding the 2.9% whole brain atrophy rate and the 2.4% gray matter loss rate 3

White Matter and Deep Gray Matter Changes

Cerebral leucoencephalopathy (white matter signal abnormalities) appears in 45-65% of JNCL patients, representing the most significant measurable alteration even in the youngest patients. 1, 2 The white matter shows increased T2/FLAIR signal intensity with statistical significance (P < 0.0001) compared to age-matched controls. 1

Thalamic T2-weighted hypointensity develops in 33-36% of JNCL patients, typically appearing from age 7 years onward. 1, 2 This finding is less frequent in juvenile-onset disease compared to infantile-onset NCL (where it occurs in 80% of cases). 2

The caudate nucleus and putamen also demonstrate low signal intensity on T2-weighted imaging, appearing from ages 11 years onward. 1

Additional Characteristic Features

Recent expanded phenotyping has identified previously underreported findings in genetically confirmed NCL cases:

  • T2/FLAIR hyperintensity in the posterior limb of internal capsule (present in 22 of 24 patients in one series) 4
  • Abnormal signal in the ventral pons (79% of cases) 4
  • Insular and subinsular region signal abnormalities (75% of cases), a finding reported for the first time in 2020 4
  • Periventricular and parieto-occipital white matter hyperintensities are particularly characteristic of late-infantile NCL but can occur in juvenile forms 2

Corpus Callosum and Brainstem Involvement

Reduction in the size of both the corpus callosum and brainstem structures occurs consistently in JNCL, though these changes may be subtle early in disease. 1

Clinical Correlation and Diagnostic Timing

Critical pitfall: MRI findings develop relatively late in JNCL, with the absence of pathological findings in very early disease stages being an important diagnostic consideration. 1 The median delay between disease onset and diagnosis is 1.5 years, with mean ages of disease onset at 4.7 years, first MRI at 6.8 years, and diagnosis at 7.3 years. 4

The MRI findings correlate significantly with clinical severity markers including decreased intelligence, speech disturbances, and motor problems, making them useful for assessing disease severity and prognosis, particularly in younger patients. 1

Progressive Nature

Follow-up imaging demonstrates progressive changes in 89% (8 of 9) of patients with serial MRI studies, with both atrophy and white matter signal abnormalities worsening over time. 4 The hippocampal volume loss of 0.85 cm³ over 5 years represents one of the most quantifiable progressive changes. 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.